Skip to main content
Equibles
ANIK logo

ANIK · Anika Therapeutics, Inc. · Metrics

Track ANIK — free

Use ANIK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANIK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$21.55 +0.20 (+0.94%) At close · Oct 28 Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Customer concentration — top customer 53% of revenue

One customer — 53% of revenue (the three-months ended June 30, 2026)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the six-months ended June 30, 2026)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the six-months ended June 30, 2025)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the three-months ended June 30, 2025)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
View the 10-Q filed Jul 29, 2026
Market Cap
$288.40M
Shares
13.38M
Volume · Oct 28 97.79K Avg daily vol (3M) 110K

ANIK metrics

91 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$21.55
Market cap
$288.40M

Price action

20 metrics
Price change (1W)
+4.5%
Price change (30D)
+3.2%
Price change (3M)
+40.9%
Price change (6M)
+39.9%
Price change (YTD)
+122.2%
Price change (1Y)
+120.1%
Trailing year
Price change (5Y)
-48.3%
52-week high
$22.03
52-week low
$9.13
Change from 52-week high
-3.1%
Change from 52-week low
+133.8%
Annualized volatility
49.4%
Annualized volatility (3M)
47.7%
Beta
0.6
RSI (14D)
60.3
Price vs SMA 50
+3.3%
Price vs SMA 200
+34.3%
Avg volume (3M)
109,298
Relative volume
0.8
Average dollar volume
$2.24M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
13.38M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.4×
reciprocal yield 42.2%
P / book
2.1
reciprocal yield 48.0%
FCF yield
0.2%
TTM · current market cap
Buyback yield
5.3%
P / FCF
508.4
reciprocal yield 0.2%
P / operating cash flow
47.8
reciprocal yield 2.1%
Earnings yield
-1.3%

Historical valuation

8 metrics
P / E historical average (3Y)
43.2×
reciprocal yield 2.3%
P / E historical average (5Y)
43.2×
reciprocal yield 2.3%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
5.3%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
62.2%
Operating margin
-4.2%
Trailing 12 months
Net margin
-3.1%
Gross profit (TTM)
$75.00M
Operating profit (TTM)
−$5.12M
Net income (TTM)
−$3.78M
Trailing 12 months
Diluted EPS (TTM)
$-0.27
FCF margin
0.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$8.66
Gross profit per diluted share (TTM)
$5.39
Operating profit per diluted share (TTM)
$-0.37
EBITDA per diluted share (TTM)
$0.03
Net income per diluted share (TTM)
$-0.27
Operating cash flow per diluted share (TTM)
$0.40
Free cash flow per diluted share (TTM)
$0.01
Capital expenditures per diluted share (TTM)
$0.39
R&D per diluted share (TTM)
$1.97
Stock compensation per diluted share (TTM)
$0.95
Book value per share
$10.33

Growth

11 metrics
Revenue growth YoY
+15.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$120.65M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-5.5%
Year over year · fewer shares
Revenue CAGR (3Y)
-0.3%
Revenue CAGR (5Y)
-2.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
-17.5%

Quality

14 metrics
Return on equity
-2.8%
Return on assets
-2.1%
Debt / equity
—
Current ratio
4.5
EBITDA (TTM)
$500,000
Free cash flow (TTM)
$562,000
Quick ratio
3.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$38.41M
Total assets
$183.47M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$5.98M
Capital expenditures (TTM)
$5.42M
R&D (TTM)
$27.45M
SG&A (TTM)
$52.67M
Stock compensation (TTM)
$13.15M
R&D / revenue
22.8%
Stock compensation / revenue
10.9%

Ownership (13F)

9 metrics
13F filers
133
13F filer change QoQ
+3
Institutional ownership
91.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
40.7%
Private-fund adviser ownership
37.1%
Active holders' share change QoQ
+4.1%
Holder tenure
15.0
Price vs estimated holder cost
-8.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
12.4%

Short interest

3 metrics
Short interest
2.7%
Latest settlement · 3.4 days to cover
Days to cover
3.4d
Short-squeeze score
55 / 100

Insider activity

2 metrics
Net insider buying (90D)
$41,060
Insider-sentiment score
77 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 898437 CUSIP 035255108 13F (30d) 25 filings 25 filers Visit website Investor relations